BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $214 from $187 and keeps a Buy rating on the shares after Q3 earnings. The firm said the reasons to own extend beyond thus far solid execution and that Brinsupri’s robust beat drove Insmed’s strength. BofA contends there’s room for further upside with the opportunity in non-cystic fibrosis bronchiectasis still not fully appreciated. The firm added that Insmed is one of the stronger stories in the space.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed price target raised to $215 from $139 at RBC Capital
- Insmed price target raised to $223 from $194 at UBS
- Strong Buy Rating for Insmed Driven by Brinsupri’s Success and Promising Pipeline
- Insmed price target raised to $217 from $171 at Wells Fargo
- Insmed’s Q3 2025 Earnings Highlight Growth and Expansion